AN2 Therapeutics Signs License Agreement With University of Georgia Research Foundation to Develop Boron-Based Therapy for Chagas Disease; To Date, Preclinical Activities Have Been Supported Using Non Dilutive Grant Funding From Wellcome
Portfolio Pulse from Benzinga Newsdesk
AN2 Therapeutics has signed a license agreement with the University of Georgia Research Foundation to develop a boron-based therapy for Chagas disease. The preclinical activities have been funded by non-dilutive grant funding from Wellcome.
October 18, 2023 | 11:03 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
AN2 Therapeutics' partnership with the University of Georgia Research Foundation for the development of a Chagas disease therapy could potentially boost the company's profile and future revenue prospects.
The partnership with the University of Georgia Research Foundation allows AN2 Therapeutics to develop a new therapy, which could potentially lead to a new revenue stream if the therapy proves successful and gets approved. This could positively impact the company's stock price in the short term due to increased investor confidence.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100